 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH, along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360 liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology ESMO 2021 virtual congress on September 16-21. While precision oncology has made a meaningful differ 